Innovative collagen-to-player medical dressing of COLGO for acute and chronic wounds (Q77871): Difference between revisions

From EU Knowledge Graph
Jump to navigation Jump to search
(‎Changed an Item: Fixing rounding issue)
(‎Removed claim: summary (P836): Reference_reference_programme_aids:SA.41471 (2015/X) _public:Article 25 of Commission Regulation (EC) No 651/2014 of 17 June 2014 declaring certain categories of aid compatible with the internal market in the application of Article 107 and 108 of the Treaty (OJ(OJ LEU L 187/1, 26.06.2014).The aim of the project is to create a new category of breakthrough and innovative medical dressings for the treatment of acute and chronic wounds, including...)
Property / summary
Reference_reference_programme_aids:SA.41471 (2015/X) _public:Article 25 of Commission Regulation (EC) No 651/2014 of 17 June 2014 declaring certain categories of aid compatible with the internal market in the application of Article 107 and 108 of the Treaty (OJ(OJ LEU L 187/1, 26.06.2014).The aim of the project is to create a new category of breakthrough and innovative medical dressings for the treatment of acute and chronic wounds, including bacterial infections whose design has been notified for patenting (application to UPRP No P.422023).Biolabinvest — the spin off, with its own plant and the technology for the production of collagen and in close cooperation with the resulting 2012 Cluster of the Centre of Industrial Engineering at WAT, which counts 52 companies and 19 Centres, decided to combine the synergies of these materials in the dressing.Scientific publications and reports on the high efficacy of anti-bacterial grafen are known, but no such material has so far been applied in a dressing, as this material is very delicate and easy to convert into volatile dust.Thanks to the specificity of collagen, which is a natural polymer and forms a matrix and a viscous structure for the permanent import and incorporation of particles of graphene.Moreover, until now, nobody has applied an economically efficient technology to its industrial manufacturing.It is only ITME & pressing;The Institute of Technology for Electronic Materials has developed a relatively cheap and efficient technology for obtaining Grafenic paper from graphene, which has the properties of a nanomaterial.Biolabinvest will be the beneficiary of this technology, as the consignee of the Grain Paper.The project is therefore to carry out research and development on optimising the structure of collagen and incorporation technology of graphene to collagen which will provide the greatest therapeutic efficacy.Bilagainwest has (English)
 
Property / summary: Reference_reference_programme_aids:SA.41471 (2015/X) _public:Article 25 of Commission Regulation (EC) No 651/2014 of 17 June 2014 declaring certain categories of aid compatible with the internal market in the application of Article 107 and 108 of the Treaty (OJ(OJ LEU L 187/1, 26.06.2014).The aim of the project is to create a new category of breakthrough and innovative medical dressings for the treatment of acute and chronic wounds, including bacterial infections whose design has been notified for patenting (application to UPRP No P.422023).Biolabinvest — the spin off, with its own plant and the technology for the production of collagen and in close cooperation with the resulting 2012 Cluster of the Centre of Industrial Engineering at WAT, which counts 52 companies and 19 Centres, decided to combine the synergies of these materials in the dressing.Scientific publications and reports on the high efficacy of anti-bacterial grafen are known, but no such material has so far been applied in a dressing, as this material is very delicate and easy to convert into volatile dust.Thanks to the specificity of collagen, which is a natural polymer and forms a matrix and a viscous structure for the permanent import and incorporation of particles of graphene.Moreover, until now, nobody has applied an economically efficient technology to its industrial manufacturing.It is only ITME & pressing;The Institute of Technology for Electronic Materials has developed a relatively cheap and efficient technology for obtaining Grafenic paper from graphene, which has the properties of a nanomaterial.Biolabinvest will be the beneficiary of this technology, as the consignee of the Grain Paper.The project is therefore to carry out research and development on optimising the structure of collagen and incorporation technology of graphene to collagen which will provide the greatest therapeutic efficacy.Bilagainwest has (English) / rank
Normal rank
 

Revision as of 10:26, 14 October 2020

Project in Poland financed by DG Regio
Language Label Description Also known as
English
Innovative collagen-to-player medical dressing of COLGO for acute and chronic wounds
Project in Poland financed by DG Regio

    Statements

    country
    Poland
    0 references
    EU contribution
    6,318,620.03 zloty
    0 references
    1,516,468.81 Euro
    exchange rate to Euro
    0.24 Euro
    point in time
    13 January 2020
    0 references
    budget
    8,704,936.05 zloty
    0 references
    2,089,184.65 Euro
    exchange rate to Euro
    0.24 Euro
    point in time
    13 January 2020
    0 references
    co-financing rate
    72.59 percent
    0 references
    start time
    1 December 2017
    0 references
    end time
    31 March 2020
    0 references
    beneficiary name (string)
    BIOLABINVEST SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
    0 references
    beneficiary
    Q2509541
    0 references
    coordinate location

    52°5'40.9"N, 20°48'27.0"E
    0 references
    summary
    Numer_referencyjny_programu_pomocowego: SA.41471(2015/X) Przeznaczenie_pomocy_publicznej: art. 25 rozporządzenia KE nr 651/2014 z dnia 17 czerwca 2014 r. uznające niektóre rodzaje pomocy za zgodne z rynkiem wewnętrznym w stosowaniu art. 107 i 108 Traktatu (Dz. Urz. UE L 187/1 z 26.06.2014). Celem projektu jest stworzenie nowej kategorii przełomowych i innowacyjnych opatrunków medycznych w leczeniu ran ostrych i przewlekłych, w tym z infekcjami bakteryjnymi, których koncepcja została zgłoszona do opatentowania (wniosek do UPRP nr P.422023). Biolabinvest - start-up typu spin-off, posiadając własny zakład i technologię produkcji kolagenu wieprzowego i blisko współpracując z powstałym 2012 roku Klastrem Centrum Inżynierii Biomedycznej przy WAT, który liczy sobie 52 firmy i 19 Ośrodków, postanowił połączyć synergię tych materiałów w opatrunku. Znane są publikacje naukowe i doniesienia o wysokiej skuteczności antybakteryjnej grafenu ale nikt do tej pory nie aplikował tego nanomateriału w opatrunku, ponieważ jest to materiał niezwykle delikatny i łato przekształca się w lotny pył. Dzięki specyfice kolagenu który jest naturalnym polimerem i tworzy macierz oraz lepką strukturę do trwałego przywierania i inkorporacji cząsteczek grafenu. Ponadto do tej pory nikt nie zastosował odpowiednio efektywnej ekonomicznie technologii do jego przemysłowego wytwarzania. Dopiero ITME – Instytut Technologii Materiałów Elektronicznych opracował relatywnie tanią i efektywną technologię otrzymywania papieru grafenowego z tlenku grafenu, posiada właściwości nanomateriału. Biolabinvest będzie beneficjantem tej technologii, jako odbiorca papieru grafenowego. Projekt więc polega na przeprowadzeniu prac badawczo-rozwojowych w zakresie optymalizacji struktury zastosowanego kolagenu i technologii inkorporacji grafenu do kolagenu, która zapewni największa skuteczność terapeutyczną. Biolabinwest dysponuje ki (Polish)
    0 references

    Identifiers

    Polish Kohesio ID
    POIR.01.01.01-00-0293/17
    0 references
     
    Retrieved from "https://linkedopendata.eu/w/index.php?title=Item:Q77871&oldid=6326068"